Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Acta Biomater. 2024 Oct 1;187:340-351. doi: 10.1016/j.actbio.2024.08.045. Epub 2024 Aug 30.
Tumor immunotherapy has gained more and more attention in tumor treatment. However, the accumulation of lactic acid in tumor tissue inhibits the response of immune cells to form an immunosuppressive microenvironment (ISME). To reverse the ISME, an acid-responsive nanoplatform (termed as MLLN@HA) is reported for synergistically enhanced tumor immunotherapy. MLLN@HA is constructed by the co-loading of lactate oxidase (LOX) and DNA repair inhibitor (NU7441) in a manganese-doped layered double hydroxide (Mn-LDH), and then modified with hyaluronic acid (HA) for tumor-targeted delivery. After endocytosis by tumor cells, MLLN@HA decomposes and releases LOX, NU7441 and Mn ions in the acidic tumor microenvironment. The released LOX catalyzes the conversion of lactic acid into hydrogen peroxide (HO), which not only alleviates the ISME, but also provides reactants for the Mn-mediated Fenton-like reaction to enhance chemodynamic therapy (CDT). Released NU7441 prevents CDT-induced DNA damage from being repaired, thereby increasing double-stranded DNA (dsDNA) fragments within tumor cells. Importantly, the released Mn ions enhance the sensitivity of cyclic GMP-AMP synthase (cGAS) to dsDNA fragments, and activate the stimulator of interferon genes (STING) to induce an anti-tumor immune response. Such an orchestrated immune-boosting strategy ultimately achieves effective tumor growth inhibition and prevents tumor lung metastasis. STATEMENT OF SIGNIFICANCE: To improve the efficacy of tumor immunotherapy, an innovative acid-responsive MLLN@HA nanoplatform was developed for synergistically enhanced tumor immunotherapy. The MLLN@HA actively targets to tumor cells through the interaction of HA with CD44, and then degrades to release LOX, NU7441 and Mn ions in the acidic tumor microenvironment. The released LOX generates HO for the Mn-mediated Fenton reaction and reverses the ISME by consuming lactate. NU7441 prevents DNA damage repair, leading to an increased concentration of free DNA fragments, while Mn ions activate the cGAS-STING pathway, enhancing the systemic anti-tumor immune response. The orchestrated immune-boosting nanoplatform effectively inhibits tumor growth and lung metastasis, presenting a promising strategy for cancer treatment.
肿瘤免疫疗法在肿瘤治疗中受到越来越多的关注。然而,肿瘤组织中乳酸的积累抑制了免疫细胞的反应,形成了免疫抑制的微环境(ISME)。为了逆转这种免疫抑制,报道了一种酸响应纳米平台(称为 MLLN@HA),用于协同增强肿瘤免疫治疗。MLLN@HA 通过在锰掺杂层状双氢氧化物(Mn-LDH)中共同装载乳酸氧化酶(LOX)和 DNA 修复抑制剂(NU7441)来构建,然后用透明质酸(HA)进行修饰以实现肿瘤靶向递送。在被肿瘤细胞内吞后,MLLN@HA 在酸性肿瘤微环境中分解并释放 LOX、NU7441 和 Mn 离子。释放的 LOX 催化乳酸转化为过氧化氢(HO),不仅缓解了 ISME,还为 Mn 介导的芬顿样反应提供了反应物,以增强化学动力学治疗(CDT)。释放的 NU7441 防止 CDT 诱导的 DNA 损伤修复,从而增加肿瘤细胞内的双链 DNA(dsDNA)片段。重要的是,释放的 Mn 离子增强了环鸟苷酸-腺苷酸合酶(cGAS)对 dsDNA 片段的敏感性,并激活干扰素基因刺激物(STING)诱导抗肿瘤免疫反应。这种协调的免疫增强策略最终实现了有效的肿瘤生长抑制并防止了肿瘤肺转移。
为了提高肿瘤免疫治疗的疗效,开发了一种创新的酸响应 MLLN@HA 纳米平台,用于协同增强肿瘤免疫治疗。MLLN@HA 通过 HA 与 CD44 的相互作用主动靶向肿瘤细胞,然后在酸性肿瘤微环境中降解释放 LOX、NU7441 和 Mn 离子。释放的 LOX 产生 HO 用于 Mn 介导的芬顿反应,并通过消耗乳酸来逆转 ISME。NU7441 防止 DNA 损伤修复,导致游离 DNA 片段浓度增加,而 Mn 离子激活 cGAS-STING 途径,增强全身抗肿瘤免疫反应。协调的免疫增强纳米平台有效地抑制肿瘤生长和肺转移,为癌症治疗提供了一种有前途的策略。